Pharmaceutical composition for the prevention or treatment of obesity in canids, containing enabogliflozin
Empagliflozin-based pharmaceuticals address obesity in dogs by reducing body condition score and metabolic indicators, enhancing health and longevity.
JP7869318B2Active Publication Date: 2026-06-02DAEWOONG PHARM CO LTD
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- DAEWOONG PHARM CO LTD
- Filing Date
- 2023-01-20
- Publication Date
- 2026-06-02
AI Technical Summary
Technical Problem
Obesity in pet dogs leads to coexisting diseases and reduces lifespan, necessitating effective management to promote a healthy life expectancy.
Method used
A pharmaceutical composition containing empagliflozin is administered to dogs to reduce body condition score, body weight, fat thickness, and other obesity indicators, improving metabolic health.
Benefits of technology
Empagliflozin effectively reduces obesity-related parameters and improves metabolic indicators in dogs, offering a therapeutic solution for obesity-related comorbidities.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 0007869318000006 
Figure 0007869318000007 
Figure 0007869318000008
Abstract
The present invention relates to a pharmaceutical composition for preventing or treating obesity in canines, comprising enavogliflozin as an active ingredient. The composition reduces the body condition score, weight, fat thickness, body fat percentage, chest circumference and waist circumference of obese dogs, and is also effective in improving serological indices, and is therefore useful for preventing or treating obesity in canines.
Need to check novelty before this filing date? Find Prior Art